ObsEva SA (NASDAQ:OBSV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “

OBSV has been the topic of several other reports. HC Wainwright started coverage on shares of ObsEva SA in a research note on Thursday, June 29th. They set a “buy” rating and a $27.00 target price on the stock. Leerink Swann reissued an “outperform” rating and set a $18.00 target price on shares of ObsEva SA in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.25.

ObsEva SA (NASDAQ OBSV) traded down 3.21% during midday trading on Friday, reaching $6.93. The company’s stock had a trading volume of 20,123 shares. The stock’s market cap is $197.48 million. ObsEva SA has a one year low of $5.00 and a one year high of $14.69. The stock’s 50 day moving average price is $7.51 and its 200-day moving average price is $8.54.

ObsEva SA (NASDAQ:OBSV) last posted its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.13. During the same period last year, the firm earned ($0.30) EPS. On average, analysts forecast that ObsEva SA will post ($2.32) EPS for the current fiscal year.

WARNING: “ObsEva SA (OBSV) Stock Rating Upgraded by Zacks Investment Research” was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/09/obseva-sa-obsv-stock-rating-upgraded-by-zacks-investment-research-2.html.

Several hedge funds have recently bought and sold shares of the company. Baker Avenue Asset Management LP purchased a new position in ObsEva SA in the 1st quarter valued at about $104,000. Paloma Partners Management Co purchased a new position in ObsEva SA in the 1st quarter valued at about $131,000. Iguana Healthcare Management LLC purchased a new position in ObsEva SA in the 1st quarter valued at about $260,000. Spark Investment Management LLC purchased a new position in ObsEva SA in the 1st quarter valued at about $518,000. Finally, Nexthera Capital LP purchased a new position in ObsEva SA in the 1st quarter valued at about $521,000. 48.46% of the stock is currently owned by institutional investors and hedge funds.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Get a free copy of the Zacks research report on ObsEva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.